September 2026 Research Update

Across these reports, the overall pattern was that unicentric Castleman disease (one main mass) was most often treated with complete surgical removal, and follow-up imaging commonly showed no recurrence. Evidence included two single-center retrospective studies (looking back at past records) and several single-patient case reports, so results describe real-world experience but are not the same as randomized trials. A recurring challenge was that scans sometimes suggested other tumors (including neuroendocrine or nerve-related tumors), and the Castleman diagnosis was confirmed only after surgery or biopsy. [1] [2] [3] [4] [5] [6] [7] [8] [9]

In a single-center series of 59 retroperitoneal (deep abdominal) Castleman disease cases, complete surgical removal led to disease-free survival in all unicentric cases over long follow-up, while all 7 multicentric cases reached disease control with combined care that could include surgery, steroids, or rituximab-based medicines. The same study noted that many unicentric retroperitoneal cases had no symptoms, and scans often showed a well-defined, strongly enhancing mass. [1]

A second single-center study focused on 75 people with retroperitoneal unicentric disease and described an "inflammatory" subtype that more often occurred with serious complications affecting skin and lungs (paraneoplastic pemphigus and bronchiolitis obliterans). Most patients had surgery, including many complete resections, and the only deaths reported were in two patients who had the inflammatory subtype and had not had the Castleman mass removed. [2]

Several reports highlighted minimally invasive approaches in the chest, including video-assisted or robot-assisted thoracic surgery, with complete removal and uneventful recovery, and no recurrence reported at short follow-up. One small retrospective series of eight people with unicentric disease inside the lung described complete thoracoscopic resection in all patients with no recurrence during follow-up averaging about 35 months, and blood inflammation marker levels normalized after surgery in the few patients where they were elevated. [6] [7] [8] [3]

Case reports in the abdomen described masses near the pancreas, in the mesentery (tissue holding the intestines), and near the adrenal gland that initially looked like other tumor types on imaging. After laparoscopic removal, pathology confirmed unicentric Castleman disease, and follow-up imaging showed no residual disease or recurrence over follow-up ranging from 1 to 2 years. Two of these reports emphasized that careful imaging review, and in some situations preoperative tissue sampling, may help surgeons plan removal while avoiding unnecessary removal of nearby organs such as the pancreas. [4] [5] [9]

For patients with unicentric Castleman disease, these papers mainly reinforce a shared real-world message: when the mass can be completely removed, many reports describe long periods without the disease coming back, including in retroperitoneal and lung locations. They also show why diagnosis can be confusing before surgery, because scans can resemble other tumors and confirmation often comes from tissue analysis. What remains uncertain is how often results differ by mass location, size, and inflammatory complications, because many publications were single-patient reports and the larger studies came from single centers.

Across these papers, the common message is that Castleman disease can be identified through detailed lymph node tissue review, sometimes unexpectedly, and that standardizing what pathologists see on biopsy slides is an active area of research. One report highlighted how Castleman disease can sit alongside another condition in the same patient, which can complicate interpretation of enlarged lymph nodes. Another study suggested that automated image analysis may help make grading of Castleman-related tissue features more consistent, but it is not yet a stand-alone diagnostic test.

In one patient with papillary thyroid cancer and neck lymph node spread, a separate, non-cancerous lymph node showed unicentric hyaline-vascular Castleman disease found incidentally during surgery and pathology review. [10] This illustrates that not every enlarged or removed lymph node in someone with cancer is automatically a metastasis, and that careful microscopic examination can reveal different causes in different nodes. [10]

A multicenter retrospective study developed a computer model to grade six Castleman disease-related tissue features on standard H&E (hematoxylin and eosin) whole-slide images. [11] In a held-out evaluation set, exact grade accuracy ranged from 0.52 to 0.68 across features, and 96.2% of model grades were within one grade of the expert reference. [11] The authors concluded this supports feasibility for standardizing how Castleman-like tissue patterns are graded, while noting external validation is still needed and the work did not try to decide whether a case was Castleman disease versus not. [11]

For patients and caregivers, these papers mainly reinforce that biopsy interpretation matters, and that more than one explanation for lymph node changes can exist in the same person. The automation study is background research aimed at improving consistency in slide reading across centers; it does not mean a computer can diagnose Castleman disease on its own yet, and it still requires further testing in other settings. Uncertainty remains about how well these tools will work across different labs, scanners, and staining differences, and how they will be used alongside expert pathology review.

Across this months papers, a consistent pattern was that multicentric Castleman disease often required systemic (whole-body) treatment, while single-area disease could respond to surgery. In idiopathic multicentric Castleman disease (iMCD), multiple reports described improvement after treatments that block the inflammatory signal interleukin-6 (IL-6), although the evidence outside the registry analysis is mainly from individual cases and small numbers. [12] [13] [14] [15] [16] [17]

In the ACCELERATE registry, children with iMCD appeared to have more severe disease at diagnosis than adults based on a severity score, but response to siltuximab with or without corticosteroids was similar between pediatric and adult groups. In that registry analysis, 12 of 14 children and 35 of 48 adults met the studys response definition. [17]

Several case reports linked specific organ problems to iMCD and described improvement after adding an IL-6 blocker. One person with lung involvement did not improve on steroids alone but improved after tocilizumab was added, with better symptoms, inflammation markers, and chest imaging. [16]

Other single-patient reports highlighted less common situations where IL-6 blockade was part of treatment. One patient with iMCD-TAFRO developed swelling (anasarca), fluid around organs (serositis), low blood counts, and kidney problems before enlarged lymph nodes were seen, and improved after corticosteroids plus siltuximab once lymph node changes were found on PET-CT. [15]

Skin and blood vessel inflammation were also described alongside iMCD in small numbers. Two iMCD patients with IgA vasculitis were reported to improve with tocilizumab, and the papers literature review noted other similar iMCD cases with IgA-related kidney or vessel disease that also improved with tocilizumab. [13]

A separate case report described a person with iMCD-NOS who had enlarging skin nodules that broke open, caused by gouty panniculitis, and widespread lymph node enlargement; after siltuximab, inflammation (CRP) normalized and anemia and high globulin levels improved, although some general symptoms continued. This suggests IL-6 blockade may improve measurable inflammation even when not all symptoms resolve quickly. [14]

A Tunisian multicenter retrospective study comparing unicentric and multicentric Castleman disease found that immediate remission was common after complete surgical removal for unicentric disease, while multicentric disease more often needed systemic treatments such as corticosteroids, anti-IL-6 therapy, or chemotherapy. Overall, full remission across the whole cohort was reported in about 44%, and deaths occurred only in the multicentric group, attributed to multiorgan failure or infection complications. [12]

Finally, one case report described Castleman disease in a person with myasthenia gravis; symptoms improved after immune treatments (intravenous immunoglobulin and steroids), and rituximab-based chemotherapy (R-CHOP) was started, but longer-term outcome was unknown because follow-up was incomplete. This single case does not show what typically happens, but it reflects that treatment plans may differ when other immune conditions are present. [18]

For patients and caregivers, these papers mainly add real-world context: multicentric Castleman disease often needs whole-body treatment, and multiple reports describe improvement when IL-6-blocking medicines were used in iMCD, including in children and in cases with lung involvement, IgA-related vasculitis/kidney disease, or TAFRO features. What remains uncertain is how well these results apply to everyone, because many reports were single-patient descriptions and the registry analysis did not fully capture side effects or long-term outcomes for all subgroups. Treatments may also vary depending on whether disease is unicentric versus multicentric and on co-existing conditions.

Across this paper, the main pattern is that TAFRO syndrome can begin with an unexpected problem outside the lymph nodes and then quickly progress to widespread inflammation and organ failure. The evidence here is limited to a single case report, so it cannot show how often this happens or predict who is at risk. [19]

In one 59-year-old man, imaging showed adrenal hemorrhage (bleeding in an adrenal gland) before thrombocytopenia (low platelet count) became clear, along with back pain and later swelling from fluid buildup. The illness then rapidly worsened with kidney problems and multiple organ failure, and the patient died despite glucocorticoid therapy. [19]

An autopsy supported TAFRO syndrome and showed thrombotic microangiopathy in the kidneys, a type of small blood vessel injury that can contribute to kidney failure. This report highlights that adrenal hemorrhage can appear early, potentially before the more recognized blood count changes are seen. [19]

For patients and caregivers, this report mainly adds background about how TAFRO syndrome may start in some people, including with adrenal bleeding and pain before typical lab changes like low platelets. Because it describes only one person, it does not prove that adrenal hemorrhage is a common early sign, and it does not clarify how often steroids fail or which tests best detect early disease.

Across three case reports, Castleman disease was described together with other health problems that drove symptoms and care: POEMS syndrome, complex regional pain syndrome (CRPS) after pelvic surgery, and paraneoplastic pemphigus affecting the mouth. Because these are single-patient reports, they highlight what can happen but cannot show how often it happens or which approach works best overall. Together, they suggest that when Castleman disease overlaps with another syndrome, monitoring both disease activity and day-to-day symptoms (like nerve problems, pain, or mouth sores) may matter for understanding recovery. [20] [21] [22]

In one woman with POEMS syndrome linked to Castleman disease and latent tuberculosis, diagnosis was challenging because early biopsies were not conclusive, and later testing showed a plasma cell disorder and high vascular endothelial growth factor (VEGF). After daratumumab, bortezomib, and dexamethasone followed by autologous stem cell transplantation, VEGF normalized and the report described biochemical remission, but nerve damage symptoms (neuropathy) continued. This emphasizes that blood markers can improve even when long-lasting symptoms remain. [20]

In a 32-year-old woman with unicentric Castleman disease, severe nerve pain developed as CRPS type 2 after pelvic neurolysis. A burst-mode spinal cord stimulation trial reduced groin and right leg pain by about 80%, and after a permanent implant the improvement continued at 3 months with the patient able to stop pregabalin; no complications were reported. This case links Castleman-related pelvic disease and later pain management needs rather than immune or blood marker changes. [21]

Another report described unicentric Castleman disease with paraneoplastic pemphigus, an autoimmune blistering condition, causing painful mouth lesions. Two courses of membrane therapeutic plasma exchange lowered serum immunoglobulin G (IgG), and the oral lesions healed with improved appetite and quality of life, without treatment-related complications in this patient. The case suggests that removing circulating antibodies may help mouth lesions heal in this specific overlap condition when other treatments have not worked, although this is a single patient. [22]

For patients and caregivers, these reports mainly serve as background information showing that Castleman disease can sometimes occur with other syndromes that strongly shape symptoms, such as neuropathy in POEMS, disabling nerve pain after pelvic procedures, or severe mouth sores from paraneoplastic pemphigus. The near-term takeaway is awareness that symptom improvement may not match lab improvement (as in persistent neuropathy despite normalized VEGF), and that symptom-focused approaches were used in individual situations. What remains uncertain is how common these overlap situations are and how well these approaches work across larger groups, since each paper describes only one person. [20] [21] [22]